|
1
|
Cormier JN and Pollock RE: Soft tissue
sarcomas. CA Cancer J Clin. 54:94–109. 2004. View Article : Google Scholar
|
|
2
|
Heare T, Hensley MA and Dell’Orfano S:
Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr.
21:365–372. 2009.
|
|
3
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gorlick R and Khanna C: Osteosarcoma. J
Bone Miner Res. 25:683–691. 2010. View
Article : Google Scholar
|
|
5
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ji HF, Li XJ and Zhang HY: Natural
products and drug discovery. EMBO Rep. 10:194–200. 2009.PubMed/NCBI
|
|
7
|
Zhao J, Jiang P and Zhang WD: Molecular
networks for the study of TCM pharmacology. Brief Bioinform.
11:417–430. 2009. View Article : Google Scholar
|
|
8
|
Rocha AB, Lopes RM and Schwartsmann G:
Natural products in anticancer therapy. Curr Opin Pharmacol.
1:364–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cragg GM, Newman DJ and Snader KM: Natural
products in drug discovery and development. J Nat Prod. 60:52–60.
1997. View Article : Google Scholar
|
|
10
|
Tu YY: The discovery of artemisinin
(qinghaosu) and gifts from Chinese medicine. Nat Med. 17:1217–1220.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nobili S, Lippi D, Witort E, Donnini M,
Bausi L, Mini E and Capaccioli S: Natural compounds for cancer
treatment and prevention. Pharmacol Res. 59:365–378. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh HP, Mittal S, Kaur S, Batish DR and
Kohli RK: Chemical composition and antioxidant activity of
essential oil from residues of Artemisia scoparia. Food
Chemistry. 114:642–645. 2009. View Article : Google Scholar
|
|
13
|
Stanko KC, Orlić S, Politeo O, Strikić F,
Kolak I, Milos M and Satovic Z: Composition and antibacterial
activities of essential oils of seven Ocimum taxa. Food
Chemistry. 119:196–201. 2010. View Article : Google Scholar
|
|
14
|
Chinese Pharmacopoeia Commission:
Pharmacopoeia of the People’s Republic of China. 1st edition.
Chemical Industry Press; pp. 226–277. 2005
|
|
15
|
Lee MH, Lee JM, Jun SH, et al: The
anti-inflammatory effects of Pyrolae herba extract through
the inhibition of the expression of inducible nitric oxide synthase
(iNOS) and NO production. J Ethnopharmacol. 112:49–54. 2007.
|
|
16
|
Lee SM, An RB, Min BS, Na MK, Lee CH, Kang
SJ, Maeng HY and Bae KH: A new naphthoquinone from Pyrola
japonica. Arch Pharm Res. 24:522–523. 2001. View Article : Google Scholar
|
|
17
|
Galván IJ, Rashed NM, Jessulat M, et al:
Antifungal and antioxidant activities of the phytomedicine
pipsissewa, Chimaphila umbellata. Phytochemistry.
69:738–746. 2008.
|
|
18
|
Kim SJ, Um JY and Lee JY:
Anti-inflammatory activity of hyperoside through the suppression of
nuclear factor-κB activation in mouse peritoneal macrophages. Am J
Chin Med. 39:171–174. 2011.PubMed/NCBI
|
|
19
|
Nikolaev SM, Nikolaeva IG, Razuvaeva YG
and Dorzhiew AM: Antioxidant activity and flavonoid composition of
the new pancreoprotective preparation Pancreophyt. Pharm Chem J.
45:279–281. 2011. View Article : Google Scholar
|
|
20
|
Tsai SJ and Yin MC: Antioxidative and
anti-inflammatory protection of oleanolic acid and ursolic acid in
PC12 cells. J Food Sci. 73:H174–H178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramos AA, Wilson CP and Collins AR:
Protective effects of ursolic acid and luteolin against oxidative
DNA damage include enhancement of DNA repair in Caco-2 cells. Mutat
Res. 692:6–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang JS, Ren TN and Xi T: Ursolic acid
induces apoptosis by suppressing the expression of FoxM1 in MCF-7
human breast cancer cells. Med Oncol. 29:10–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Limami Y, Pinon A, Leger DY, Mousseau Y,
Moreau JC, Beneytout JL, Delage C, Liagre B and Simon A: HT-29
colorectal cancer cells undergoing apoptosis overexpress COX-2 to
delay ursolic acid-induced cell death. Biochimie. 93:749–757. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang CY, Lin CY, Tsai CW and Yin MC:
Inhibition of cell proliferation, invasion and migration by ursolic
acid in human lung cancer cell lines. Toxicol in Vitro.
25:1274–1280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shan JZ, Xuan YY, Ruan SQ and Sun M:
Proliferation-inhibiting and apoptosis-inducing effects of ursolic
acid and oleanolic acid on multi-drug resistance cancer cells in
vitro. Chin J Integr Med. 17:607–611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chinese Pharmacopoeia Commission:
Pharmacopoeia of the People’s Republic of China. Chemical Industry
Press; pp. 64–65. 2000
|
|
27
|
Bacci G, Ferrari S, Bertoni F, Ruggieri P,
Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M and
Campanacci M: Long-term outcome for patients with nonmetastatic
osteosarcoma of the extremity treated at the istituto ortopedico
rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2
protocol: an updated report. J Clin Oncol. 18:4016–4027. 2000.
|
|
28
|
Stefano F and Emanuela P: Adjuvant and
neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr
Opin Oncol. 19:341–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lamoureux F, Trichet V, Chipoy C,
Blanchard F, Gouin F and Redini F: Recent advances in the
management of osteosarcoma and forthcoming therapeutic strategies.
Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nurse P: Ordering S phase and M phase in
the cell cycle. Cell. 79:547–550. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang M, Xie R, Hou W, Wang B, Shen R,
Wang X, Wang Q, Zhu T, Jonason JH and Chen D: PTHrP prevents
chondrocyte premature hypertrophy by inducing cyclin-D1-dependent
Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal
degradation. J Cell Sci. 122:1382–1389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Haraken S, Abu-EI-Ardat K, Diab-Assaf M,
Niedzwiecki A, EI-Sabban M and Rath M: Epigallocatechin-3-gallate
induces apoptosis and cell cycle arrest in HTLV-1-positive and
-negative leukemia cells. Med Oncol. 25:30–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kessel D and Luo Y: Cells in
cryptophycin-induced cell-cycle arrest are susceptile to apoptosis.
Cancer Lett. 151:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zafonte BT, Hulit J, Amanatullah DF,
Albanese C, Wang CG, Rosen E, Reutens A, Sparano JA, Lisanti MP and
Pestell RG: Cell-cycle dysregulation in breast cancer: breast
cancer therapies targeting the cell cycle. Front Biosci.
5:d938–d961. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen JJ, Jackson PK, Kirschner MW and
Dutta A: Separate domains of p21 involved in the inhibition of Cdk
kinase and PCNA. Nature. 374:386–388. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goubin F and Ducommun B: Identification of
binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.
Oncogene. 10:2281–2287. 1995.PubMed/NCBI
|
